Clinical Pharmacokinetics: Applications in Pediatric Practice

  • Denise L. Howrie
  • Carol G. Schmitt

The statement “Children are not little adults” is a foundation of pediatric drug therapy referring to well-documented differences in pharmacokinetics and pharmacodynamics existing between children and adults. It is, therefore, important to understand the influence of age on drug disposition, especially in neonates and infants, and resulting effects on drug activity. This chapter provides brief discussions of principles of pediatric pharmacokinetics and knowledge of the effects of disease states on disposition of cardiovascular drugs affecting safe and effective drug therapy.


Continuous Renal Replacement Therapy Hepatic Blood Flow Total Body Water Cardiovascular Drug Pediatric Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G. Understanding drugs in children: pharmacokinetic maturation. Pediatr Rev 2005;26:321–327.PubMedCrossRefGoogle Scholar
  2. 2.
    Pal VB, Nahata MC. Drug Dosing in Pediatric Patients. In: Murphy JE, ed. Clinical Pharmacokinetics, 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc, pp. 439–465, 2001.Google Scholar
  3. 3.
    Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157–1167.PubMedCrossRefGoogle Scholar
  4. 4.
    Benedetti MS, Blates EL. Drug metabolism and disposition in children. Fund Clin Pharmacol 2003;17:281–299.CrossRefGoogle Scholar
  5. 5.
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants. Clin Pharmacokinet 2002;41:1077–1094.PubMedCrossRefGoogle Scholar
  6. 6.
    deWildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485–505.CrossRefGoogle Scholar
  7. 7.
    Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 2006;22:329–345.PubMedCrossRefGoogle Scholar
  8. 8.
    Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000;40:11–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Trujillo TC, Nolan PE. Antiarrhythmic agents. Drug Safety 2000;23:509–532.PubMedCrossRefGoogle Scholar
  10. 10.
    Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalized patients—frequent but most clinically insignificant. Eur J Clin Pharmacol 2005;61:675–681.PubMedCrossRefGoogle Scholar
  11. 11.
    Malone DC, Hutchins DS, Haupert H, Hansten P, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health-Syst Pharm 2005;62:1983–1991.PubMedCrossRefGoogle Scholar
  12. 12.
    Novak PH, Ekins-Daukes S, Simpson CR, Milne RM, Helms P, McLay JS. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. Brit J Clin Pharmacol 2005;59:712–717.CrossRefGoogle Scholar
  13. 13.
    Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162:405–412.PubMedCrossRefGoogle Scholar
  14. 14.
    Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281–297.PubMedCrossRefGoogle Scholar
  15. 15.
    Stump AL, Mayo T, Blum A. Management of grapefruit-drug interactions. Amer Family Physicians 2006;74:605–608.Google Scholar
  16. 16.
    Rodighiero V. Effects of liver disease on pharmacokinetics. Clin Pharmacokinet 1999;37:399–431.PubMedCrossRefGoogle Scholar
  17. 17.
    Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy. Pediatr Drugs 2004;6:45–65.CrossRefGoogle Scholar
  18. 18.
    Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998;32:362–375.PubMedCrossRefGoogle Scholar
  19. 19.
    Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin N Am 2005;89:649–687.PubMedCrossRefGoogle Scholar
  20. 20.
    Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255–271.PubMedCrossRefGoogle Scholar
  21. 21.
    Hines RN, McCarver DG. Pharmacogenomics and the future of drug therapy. Pediatr Clin N Am 2006;53:591–619.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Denise L. Howrie
    • 1
  • Carol G. Schmitt
    • 2
  1. 1.Pharmacy and PediatricsUniversity of Pittsburgh School of Pharmacy and MedicinePittsburghUSA
  2. 2.School of Pharmacy University of PittsburghChildren's Hospital of Pittsburgh of UPMCPittsburghUSA

Personalised recommendations